# Osimertinib in First and Second Line Treatment of NSCLC Harboring EGFR Mutations From Circulating Tumor DNA

> **NCT02769286** · PHASE2 · COMPLETED · sponsor: **Chonnam National University Hospital** · enrollment: 38 (actual)

## Conditions studied

- Lung Neoplasms
- EGFR Gene Mutations

## Interventions

- **DRUG:** Osimertinib

## Key facts

- **NCT ID:** NCT02769286
- **Lead sponsor:** Chonnam National University Hospital
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2016-08
- **Primary completion:** 2018-12
- **Final completion:** 2020-05
- **Target enrollment:** 38 (ACTUAL)
- **Last updated:** 2021-08-03


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02769286

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02769286, "Osimertinib in First and Second Line Treatment of NSCLC Harboring EGFR Mutations From Circulating Tumor DNA". Retrieved via AI Analytics 2026-06-01 from https://api.ai-analytics.org/clinical/NCT02769286. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*